H
HealSun Biopharm
Healsun Biopharm is a pharmaceutical company
About HealSun Biopharm
HS Biopharm operates in the biopharmaceutical industry, focusing on the development and optimization of CHO (Chinese Hamster Ovary) cell lines for the production of therapeutic proteins and monoclonal antibodies. The company serves pharmaceutical and biotechnology clients who require high-quality cell lines for drug development and manufacturing. HS Biopharm's business model revolves around providing end-to-end solutions, from DNA transfection to commercial-scale production, ensuring high yield and quality. Revenue is generated through project-based contracts and long-term partnerships with clients. The company leverages advanced technologies and proprietary methodologies to optimize cell culture processes, including pH and temperature shifts, seed density adjustments, and bioreactor tuning. This approach allows for efficient and scalable production, meeting the stringent regulatory requirements of the biopharmaceutical market.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Nov 2025 | $44M | $550M | Betta Pharmaceuticals | ↗ |
| SERIES BOther financing | Oct 2023 | $28M | $481M | China Medical System Holdings · Oriental Fortune | ↗ |
Growth signals
Latest recorded traffic for HealSun Biopharm is 1K monthly website visits, up 376.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
HealSun Biopharm in the Hangzhou ecosystem
The HealSun Biopharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
- SISinowisdom
- HCHaibang Capital
- YCYinxinggu Capital
- SFShanghai Biomedical Industrial Equity Investment Fund
- HCHT Capital
- XDXinghua Dingli
China Medical System Holdings- OFOriental Fortune
Series B and later1 investor entered at this stage
- BPBetta Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HealSun Biopharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HealSun Biopharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









